Edgewise Therapeutics, Inc. Common Stock

EWTX · Pharmaceutical Preparations · $4.9B
Powering up
EWTX
$45.32
▼ −3.45%
09/18 O 46.79 H 46.93 L 45.32 C 45.32 ▼ −3.45%
Vol 2.0M RS 96
RS rating96
Now vs pivot (%)+11.17%
Tightening (ATR ratio)1.05×
Volume dry-up1.00×
Up/down volume, net0.06
From 52-week high7%
squatplayed out
Previous breakout trailed out ▼ −4.07% in Mar
Powering up
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

The read

The base has run 3.2 weeks and fell 24% from its ceiling at its deepest. The pivot is $40.77, and the stock closed 11.2% above that pivot. Its relative strength rating is 96.

Peers
Catalyst roadmap
  1. EarningstentativeLLY · competitorin 41d
    LLY reports
    Oct 29, 2026
  2. Earningstentativein 48d
    Quarterly earnings
    Nov 5, 2026
Flagged by the market sweep

Nothing flagged for this company on the last market sweep.

In the news
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?Zacks Investment Research · 2026-09-04Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?Zacks Investment Research · 2026-09-02

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Edgewise Therapeutics, Inc. Common Stock (EWTX) — The Tape